Natixis’s Eli Lilly LLY Stock Holding History

Natixis’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100,000	Closed	-$81.3M	–	1112
2025 Q1	$81.3M	Buy	+100,000	New	+$83.2M	0.44%	37

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Natixis's LLY Position: Q2 2026 in Review

Natixis increased its Eli Lilly (LLY) stake by 32% in Q2 2026, buying an estimated $33.2M and bringing the position to 133,441 shares worth $160M. The position accounts for 0.64% of the portfolio, ranked #24.

Natixis first reported a position in LLY in Q2 2013 and has held it in 45 quarters since. The position peaked at $267M in Q1 2025. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Natixis held 133,441 shares of Eli Lilly worth $160M as of Q2 2026.
Natixis bought 32,494 Eli Lilly shares in Q2 2026, an estimated $33.2M.
Eli Lilly made up 0.64% of Natixis's portfolio in Q2 2026, its #24 holding.
Natixis first reported a position in Eli Lilly in Q2 2013 and has held it in 45 quarters since.
Natixis's Eli Lilly position peaked at $267M in Q1 2025.
4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.